From molecular mechanisms of cardiac development to genetic substrate of congenital heart diseases

Future Cardiology

Volumn 6, Issue 3, 2010, Pages 373-393

  Cecchetto, Antonella ^a   Rampazzo, Alessandra ^a   Angelini, Annalisa ^a   Bianco, Lucia Dal ^a   Padalino, Massimo ^a   Stellin, Giovanni ^a   Daliento, Luciano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cardiac development; Congenital heart disease; Genetic mutations; Homeobox; Transcription factor; Wild type mutation

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CBPEP300 INTERACTING TRANSACTIVATOR WITH ED RICH TAIL 2 PROTEIN; FIBROBLAST GROWTH FACTOR; FORKHEAD TRANSCRIPTION FACTOR; INSULIN GENE ENHANCER PROTEIN ISLET 1; MYOCYTE ENHANCER FACTOR 2; PROTEIN HAND1; PROTEIN HAND2; PROTEIN PITX2C; PROTEIN TBX1; PROTEIN TBX20; SAL LIKE 4 PROTEIN; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 5; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR TBX5; UNCLASSIFIED DRUG; WNT PROTEIN; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN MULTITYPE 2;

CELL MATURATION; CONGENITAL HEART DISEASE; EMBRYO DEVELOPMENT; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ANALYSIS; HEART ATRIUM SEPTUM DEFECT; HEART DEVELOPMENT; HEART MUSCLE CELL; HUMAN; MOLECULAR MECHANICS; NONHUMAN; NONSYNDROMIC CONGENITAL HEART DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SYNDROMIC CONGENITAL HEART DISEASE;

ANIMALS; DNA-BINDING PROTEINS; HEART; HEART DEFECTS, CONGENITAL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; TRANSCRIPTION FACTORS;

EID: 77952511899     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.10     Document Type: Review

References (198)

1. Mitchell SC, Korones SB, Berendes HW: Congenital heart disease in 56109 births incidence and natural history. Circulation 43, 323-332 (1971).
2. Hoffman JIE: Incidence, mortality and natural history. In: Pediatric Cardiology. Anderson RH, Baker EJ, Macartney FJ et al. (Eds). Churchill Livingstone, London, UK 111-139 (2002). An essential and explicative article on the general view of congenital heart disease.
3. Schultheiss TM, Burch JB, Lassar AB: A role for bone morphogenetic proteins in the induction of cardiac myogenesis. Genes Dev. 11, 451-462 (1997).
4. Winnier G, Blessing M, Labosky PA, Hogan BL: Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 9, 2105-2116 (1995).
5. Zhang H, Bradley A: Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 122, 2977-2986 (1996).
6. Monzen K, Shiojima I, Hiroi Y, Kudoh S, Oka T, Takimoto E: Bone morphogenetic proteins induce cardiomyocyte differentiation through the mitogen activated protein kinase kinase kinase TAK1 and cardiac transcription factors Csx/Nkx-2.5 and GATA-4. Mol. Cell. Biol. 19, 7096-7105 (1999).
7. Lee KH, Evans S, Ruan TY, Lassar AB: SMAD-mediated modulation of YY1 activity regulates the BMP response and cardiac specific expression of a GATA4/5/6-dependent chick Nkx2.5 enhancer. Development 131, 4709-4723 (2004).
8. Kasahara H, Usheva A, Ueyama T, Aoki H, Horikoshi N, Izumo S:. Characterization of homo- and heterodimerization of cardiac Csx/Nkx2.5 homeoprotein. J. Biol. Chem. 276, 4570-4580 (2001).
9. Kasahara H, Izumo S: Identification of the in vivo casein kinase II phosphorylation site within the homeodomain of the cardiac tissue specifying homeobox gene product Csx/Nkx2.5. Mol. Cell. Biol. 19, 526-536 (1999).
10. Akazawa H, Komuro I: Cardiac transcription factor Csx/Nkx2.5: its role in cardiac development and disease. Pharmacol. Ther. 107, 252-268 (2005).
11. McAnally CJ, Richardson JA, Olson EN: Cardiac-specific activity of an Nkx-2.5 enhancer requires an evolutionarily conserved Smad binding site. Dev. Biol. 244, 257-266 (2002).
12. Wu X, Golden K, Bodmer R: Heart development in Drosophila requires the segment polarity gene wingless. Dev. Biol. 169, 619-628 (1995).
13. Park M, Wu X, Golden K, Axelrod JD, Bodmer R: The wingless signaling pathway is directly involved in Drosophila heart development. Dev. Biol. 177, 104-116 (1996).
14. Schneider VA, Mercola M: Wnt antagonism initiates cardiogenesis in Xenopus laevis. Genes Dev. 15, 304-315 (2001).
15. Pandur P, Lasche M, Eisenberg LM, Kuhl M: Wnt-11 activation of a noncanonical Wnt signalling pathway is required for cardiogenesis. Nature 418, 636-641 (2002).
16. Alfieri CM, Cheek J, Chakraborty S, Yutzey KE: Wnt signaling in heart valve development and osteogenic gene induction. Dev. Biol. 338, 127-135 (2010).
17. Gisselbrecht S, Skeath JB, Doe CQ, Michelson AM: Heartless encodes a fibroblast growth factor receptor (DFR1/DFGF-R2) involved in the directional migration of early mesodermal cells in the Drosophila embryo. Genes Dev. 10, 3003-3017 (1996).
18. Amaya E, Musci TJ, Kirschner MW: Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos. Cell 66, 257-270 (1991).
19. Azpiazu N, Frasch M: Tinman and bagpipe - two homeobox genes that determine cell fates in the dorsal mesoderm of Drosophila. Genes Dev. 7, 1325-1340 (1993).
20. Baker R, Schubiger G: Ectoderm induces muscle specific gene expression in Drosophila embryos. Development 121, 1387-1398 (1995).
21. Reifers F, Walsh EC, Leger S, Stainier DY, Brand M: Induction and differentiation of the zebrafish heart requires fibroblast growth factor 8 (FGF8/acerebellar). Development 127, 225-235 (2000).
22. Alsan BH, Schultheiss TM: Regulation of avian cardiogenesis by FGF8 signaling. Development 129, 1935-1943 (2002).
23. Meyers EN, Martin GR: Differences in left-right axis pathways in mouse and chick: function of FGF8 and SHH. Science 285, 403-406 (1999).
24. Naito AT, Tominaga A, Oyamada M, Oyamada Y, Shiraishi I, Monzen K: Early stage-specific inhibitions of cardiomyocyte differentiation and expression of Csx/Nkx-2.5 and GATA-4 by phosphatidylinositol 3-kinase inhibitor LY294002. Exp. Cell Res. 291, 56-69 (2003).
25. Kim Y, Nirenberg M: Drosophila NK-homeobox genes. Proc. Natl Acad. Sci. USA 86, 7716-7720 (1989).
26. Komuro I, Izumo S: Csx: a murine homeobox-containing gene specifically expressed in the developing heart. Proc. Natl Acad. Sci. USA 90, 8145-8149 (1993).
27. Lints TJ, Parsons LM, Hartley L, Lyons I, Harvey RP: Nkx-2.5: a novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants. Development 119, 419-431 (1993).
28. Harvey RP: NK2 homeobox genes and heart development. Dev. Biol. 178, 203-216 (1996).
29. McElhinney DB, Geiger E, Blinder J, Benson DW, Goldmuntz E: NKX2.5 mutations in patients with congenital heart disease. J. Am. Coll. Cardiol. 42, 1650-1655 (2003). NKX 2.5 is an important transcription factor essential for cardiac development; its mutation caused congenital heart disease as described in this article.
30. Ellitt D, Solloway M, Wise N et al.: A tyrosine-rich domain within homeodomain transcription factor Nkx2.5 is an essential element in the early cardiac transcriptional regulatory machinery. Development 133, 1311-1322 (2006).
31. Kasahara, H, Bartunkova S, Schinke M, Tanaka M, Izumo S: Cardiac and extracardiac expression of Csx/Nkx2.5 homeodomain protein. Circ. Res. 82, 936-946 (1998).
32. Stanley EG, Biben C, Elefant A, Barnett L, Koentgen F, Robb L: Efficient Cre-mediated deletion in cardiac progenitor cells conferred by a 3'UTR-ires-Cre allele of the homeobox gene Nkx2-5. Int. J. Dev. Biol. 46, 431-439 (2002).
33. Thomas PS, Kasahara H, Edmonson AM, Izumo S, Yacoub MH, Barton PJ: Elevated expression of Nkx-2.5 in developing myocardial conduction cells. Anat. Rec. 263, 307-313 (2001).
34. Lien CL, Wu C, Mercer B, Webb R, Richardson JA, Olson EN: Control of early cardiac-specific transcription of Nkx2-5 by a GATA-dependent enhancer. Development 126, 75-84 (1999).
35. Searcy RD, Vincent EB, Liberatore CM, Yutzey KE: A GATA-dependent Nkx-2.5 regulatory element activates early cardiac gene expression in transgenic mice. Development 125, 4461-4470 (1998).
36. Reecy JM, Li X, Yamada M, DeMayo FJ, Newman CS, Harvey RP: Identification of upstream regulatory regions in the heartexpressed homeobox gene Nkx2-5. Development 126, 839-849 (1999).
37. Brown III CO, Chi X, Garcia-Gras E, Shirai M, Feng XH, Schwartz R J: The cardiac determination factor, Nkx2-5, is activated by mutual cofactors GATA-4 and Smad1/4 via a novel upstream enhancer. J. Biol. Chem. 279, 10659-10669 (2004).
38. Pashmforoush M, Lu JT, Chen H: Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leds to progressive cardiomyopathy and complete heart block. Cell 117, 373-386 (2004).
39. Prall OW: An Nkx2.5/Bmp/Smad1 negative feedback loop controls heart progenitor specification e proliferation. Cell 128, 947-959 (2007).
40. Molkentin JD: The zinc finger-containing transcription factors GATA-4, -5 and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J. Biol. Chem. 275, 38949-38952 (2000).
41. Molkentin JD, Lin Q, Duncan SA, Olson EN: Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev. 11, 1061-1072 (1997).
42. Kuo CT, Morrisey EE, Anandappa R et al.: GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev. 11, 1048-1060 (1997).
43. Reiter JF, Alexander J, Rodaway A et al.: Gata5 is required for the development of the heart and endoderm in zebrafish. Genes Dev. 13, 2983-2995 (1999).
44. Morrisey EE, Tang Z, Sigrist K et al.: GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo. Genes Dev. 12, 3579-3590 (1998).
45. Koutsourakis M, Langeveld A, Patient R, Beddington R, Grosveld F: The transcription factor GATA6 is essential for early extraembryonic development. Development 126, 723-732 (1999).
46. Gajewski K, Fossett N, Molkentin JD, Schulz RA: The zinc finger proteins Pannier and GATA4 function as cardiogenic factors in Drosophila. Development 126, 5679-5688 (1999).
47. Searcy RD, Vincent EB, Liberatore CM, Yutzey KE: A GATA-dependent Nkx-2.5 regulatory element activates early cardiac gene expression in transgenic mice. Development 125, 4461-4470 (1998).
48. Lien CL, Wu C, Mercer B, Webb R, Richardson JA, Olson EN: Control of early cardiac-specific transcription of Nkx2-5 by a GATA-dependent enhancer. Development 126, 75-84 (1999).
49. Davis DL, Wessels A, Burch JB: An Nkx-dependent enhancer regulates GATA-6 gene expression during early stages of heart development. Dev. Biol. 217, 310-322 (2000).
50. Molkentin JD, Antos C, Mercer B, Taigen T, Miano JM, Olson EN: Direct activation of a GATA6 cardiac enhancer by Nkx2.5: evidence for a reinforcing regulatory network of Nkx2.5 and GATA transcription factors in the developing heart. Dev. Biol. 217, 301-309 (2000).
51. Garg V, Kathiriya IS, Barnes R et al.: GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424, 443-447 (2003).
52. Okubo A, Miyoshi O, Baba K et al.: A novel GATA4 mutation completely segregated with atrial septal defect in a large Japanese family. J. Med. Genet. 41, E97 (2004).
53. Rajagopal SK, Ma Q, Obler D et al.: Spectrum of heart disease associated with murine and human GATA4 mutation. J. Mol. Cell. Cardiol. 43, 677-685 (2007).
54. Gajewski K, Kim Y, Lee YM, Olson EN, Schulz RA: D-MEF2 is a target for Tinman activation during Drosophila heart development. EMBO J. 16, 515-522 (1997).
55. Dodou E, Verzi MP, Anderson JP, Xu S-M, Black BL: MEF2c is a direct transcriptional target of ISL1 and GATA factors in the anterior heart field during mouse embryonic development. Development 131, 3931-3942 (2004). Discusses a new topic and new studies about transcription factors.
56. Nguyen HT, Bodmer R, Abmayr SM, McDermott JC, Spoerel NA: D-mef2: a Drosophila mesoderm-specific MADS box-containing gene with a biphasic expression profile during embryogenesis. Proc. Natl Acad. Sci. USA 91, 7520-7524 (1994).
57. Lilly B, Galewsky S, Firulli AB, Schulz RA, Olson EN: D-MEF2: a MADS box transcription factor expressed in differentiating mesoderm and muscle cell lineages during Drosophila embryogenesis. Proc. Natl Acad. Sci. USA 91, 5662-5666 (1994).
58. Lilly B, Zhao B, Ranganayakulu G, Paterson BM, Schulz RA, Olson EN: Requirement of MADS domain transcription factor D-MEF2 for muscle formation in Drosophila. Science 267, 688-693 (1995).
59. Lin Q, Schwarz J, Bucana C, Olson EN: Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276, 1404-1407 (1997).
60. Naya FJ, Black BL, Wu H et al.: Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat. Med. 8, 1303-1309 (2002).
61. Moleketin JD, Firulli AB, Black BL et al.: MEF2B is a potent transactivator expressed in early myogenic lineages. Mol. Cell. Biol. 16, 3814-3824 (1996).
62. Belaguli NS, Sepulveda JL, Nigam V, Charron F, Nemer M, Schwartz RJ: Cardiac tissue enriched factors serum response factor and GATA-4 are mutual co-regulators. Mol. Cell. Biol. 20, 7550-7558 (2000).
63. Wang D, Chang PS, Wang Z et al.: Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 105, 851-862 (2001).
64. Shin C, Liu Z, Passier R et al.: Modulation of cardiac growth and development by HOP, an unusual homeodomain protein. Cell 110, 725-735 (2002).
65. Chen F, Kook H, Milewski R et al.: Hop is an unusual homeobox gene that modulates cardiac development. Cell 110, 713-723 (2002).
66. Parlakian A, Tuil D, Hamard G et al.: Targeted inactivation of serum response factor in the developing heart results in myocardial defects and embryonic lethality Mol. Cell. Biol. 24, 5281-5289 (2004). Interesting and useful for the comprehension of the topic.
67. Arsenian S, Weinhold B, Oelgeschlager M, Ruther U, Nordheim A: SRF is essential for mesoderm formation during mouse embryogenesis. EMBO J. 17, 6289-6299 (1998).
68. -/- ES cells display non-cell-autonomous impairment in mesodermal differentiation. EMBO J. 19, 5845-5844 (2000).
69. Firulli AB: A handful of questions: the molecular biology of the heart and neural crest derivatives (HAND) -subclass of basic helix-loop-helix transcription factors. Gene 312, 27-40 (2003).
70. Srivastava D, Thomas T, Lin Q, Kirby ML, Brown D, Olson EN: Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND. Nat. Genet. 16, 154-160 (1997). (Pubitemid 27240613)
71. Firulli AB, McFadden DG, Lin Q, Srivastava D, Olson EN: Heart and extra embryonic mesodermal defects in mouse embryos lacking the bHLH transcription factor Hand1. Nat. Genet. 18, 266-270 (1998).
72. Riley P, Anson-Cartwright L, Cross JC: The Hand1 bHLH transcription factor is essential for placentation and cardiac morphogenesis. Nat. Genet. 18, 271-275 (1998).
73. Yamagishi H, Yamagishi C, Nakagawa O, Harvey RP, Olson EN, Srivastava D: The combinatorial activities of Nkx2.5 and dHAND are essential for cardiac ventricle formation. Dev. Biol. 239, 190-203 (2001).
74. Dai YS, Cserjesi P, Markham BE, Molkentin JD: The transcription factors GATA4 and dHAND physically interact to synergistically activate cardiac gene expression through a p300-dependent mechanism. J. Biol. Chem. 277, 24390-24398 (2002).
75. Thattaliyath BD, Firulli BA, Firulli AB: The basic-helix-loop-helix transcription factor HAND2 directly regulates transcription of the atrial naturetic peptide gene. J. Mol. Cell. Cardiol. 34, 1335-1344 (2002).
76. Papaioannou VE, Silver LM: The T-box gene family. Bioessays 20, 9-19 (1998).
77. Bruneau BG, Logan M, Davis N et al.: Chamber-specific cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. Dev. Biol. 211, 100-108 (1999).
78. Bruneau BG, Nemer G, Schmitt JP et al.: A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 106, 709-721 (2001).
79. Hiroi Y, Kudoh S, Monzen K et al.: Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. Nat. Genet. 28, 276-280 (2001).
80. Plageman TF Jr, Yutzey KE: Differential expression and function of Tbx5 and Tbx20 in cardiac development. J. Biol. Chem. 279, 19026-19034 (2004).
81. Sinh MK, Christoffels VM, Dias JM et al.: Tbx20 is essential for cardiac chamber differentiation and repression of Tbx2. Development 132, 2697-2707 (2005).
82. Yamagagishi H, Maeda J, Uchida K et al.: Molecular embryology for an understanding of congenital heart disease. Anat. Sci. Int. 84 (3), 88-94 (2009).
83. Aruga J: The role of Zic genes in neural development. Mol. Cell. Neurosci. 26, 205-221 (2004).
84. Carrel T, Purandar SM, Harrison W et al.: The X-linked mouse mutation Bent tail is associated with a deletion of the Zic3 locus. Hum. Mol. Genet. 9, 1937-1942 (2000).
85. Purandare SM, Ware SM, Kwan KM et al.: A complex syndrome of left-right axis, central nervous system and axial skeleton defects in Zic3 mutant mice. Development 129, 2293-2302 (2002).
86. Aruga J: The role of Zic genes in neural development. Mol. Cell. Neurosci. 26, 205-221 (2004).
87. Carrel T, Purandar SM, Harrison W et al.: The X-linked mouse mutation Bent tail is associated with a deletion of the Zic3 locus. Hum. Mol. Genet. 9, 1937-1942 (2000).
88. Purandare SM, Ware SM, Kwan KM et al.: A complex syndrome of left-right axis, central nervous system and axial skeleton defects in Zic3 mutant mice. Development 129, 2293-2302 (2002).
89. Sweetman D, Munsterberg A: The vertebrate spalt genes in development and disease. Dev. Biol. 293, 285-293 (2006).
90. Koshiba-Takeuchi K, Takeuchi JK, Arruda EP et al.: Cooperative and antagonistic interactions between Sall4 and Tbx5 pattern the mouse limb and heart. Nat. Genet. 38, 175-183 (2006).
91. Sakaki-Yumoto M, Kobayashi C, Sato A et al.: The murine homolog of SALL4, a causative gene in Okihiro syndrome, is essential for embryonic stem cell proliferation, and cooperates with Sall1 in ano-rectal, heart, brain and kidney development. Development 133, 3005-3013 (2006).
92. Leung, MK, Jones T, Michels CL, Livingston DM, Bhattacharya S: Molecular cloning and chromosomal localization of the human CITED2 gene encoding p35srj/Mrg1. Genomics 61, 307-313 (1999).
93. Zhao F, Lufkin T, Gelb BD: Expression of Tfap2d, the gene encoding the transcription factor Ap-2 d, during mouse embryogenesis. Gene Exp. Patterns 3, 213-217 (2003).
94. Bamforth S, Braganca J, Schneider JE et al.: Cited2 controls left-right patterning and heart development through a Nodal-Pitx2c pathway. Nat. Genet. 36, 1189-1195 (2004).
95. Bamforth SD: Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator. Nat. Genet. 29, 469-474 (2001).
96. Weninger WJ, Floro KL, Bennett MB et al.: Cited2 is required both for heart morphogenesis and establishment of the left-right axis in mouse development. Development 132, 1337-1348 (2005).
97. Meyers EN, Martin GR: Difference in left-right axis pathways in mouse and chick: function of FGF8 and SHH. Science 285, 403-406 (1999).
98. Schlange T, Arnold HH, Brand T: Bmp2 is a positive regulator of nodal signaling during left-right axis formation in the chicken embryo. Development 129, 3421-3429 (2002).
99. Kumar A, Novoselov V, Celeste AJ, Wolfmann NM, Dijke P, Kuehn MR: Nodal signaling uses activin and transforming growth factor-β receptor-regulated Smads. J. Biol. Chem. 276, 656-661 (2001).
100. Kitamura K, Miura H, Miyagawa-Tomita S et al.: Mouse Pitx2 deficiency leads to anomalies of the ventral body wall, heart, extra and peri-ocular mesoderm and right pulmonary isomerism. Development 126, 5749-5758 (1999).
101. Nowotschin S, Liao J, Gage PJ, Epstein JA, Campione M, Morrow BE: Tbx1 affects asymmetric cardiac morphogenesis by regulating Pitx2 in the secondary heart field. Development 133, 1565-1573 (2006).
102. Svensson EC, Tufts RL, Polk CE, Leiden JM: Molecular cloning of ZFPM2/FOG2: a modulator of transcription factor GATA4 in cardiomyocytes. Proc. Natl Acad. Sci. USA 96, 956-961 (1999).
103. Svensson EC, Huggins GS, Lin H et al.: A syndrome of tricuspid atresia in mice with a targeted mutation of the gene encoding ZFPM2/FOG2. Nat. Genet. 25, 353-356 (2000).
104. Tevosian SG, Deconinck AE, Tanaka M et al.: ZFPM2/FOG2, a cofactor for GATA transcription factors, is essential for heart morphogenesis and development of coronary vessels from epicardium. Cell 101, 729-739 (2000).
105. Tanizawa Y, Riggs AC, Dagogo-Jack S et al.: Isolation of the human LIM/homeodomain gene islet-1 and identification of a simple sequence repeat polymorphism. Diabetes 43 (7), 935-941 (1994). (Pubitemid 24196428)
106. Pfaff SL, Mendelsohn M, Stewart CL, Edlund T, Jessell TM: Requirement for LIM Homeobox gene Isl1 in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation. Cell 84, 309-320 (1996).
107. Cai CL, Liang X, Shi Y et al.: Isl1 identiflies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev. Cell 5, 877-889 (2003).
108. Karlsson O, Thor S, Norberg T, Ohlsson H, Edlund T: Insulin gene enhancer binding protein Isl-1 is a member of a novel class of proteins containing both a homeo- and a Cys- His domain. Nature 344, 879-882 (1990).
109. Clark EB: Mechanisms in the pathogenesis of congenital heart disease. In: The Genetics of Cardiovascular Disease. Pierpont ME, Moller J (Eds). Martinus-Nijoff, Boston, MA, USA 3-11 (1986). Interesting historical article.
110. Clark EB: Pathogenetic mechanisms of congenital cardiovascular malformations revisited. Semin. Perinatol. 20, 465-472 (1996).
111. Rosenberg HS, Oppenheimer EH, Esterly JR: Congenital rubella syndrome: the late effects and their relation to early lesions. Perspect. Pediatr. Pathol. 6, 183-202 (1981).
112. Kumar SD, Dheen ST, Tay SS: Maternal diabetes induces congenital heart defect in mice by altering the expression of genes involved in cardiovascular development. Cardiovasc. Diabetol. 6, 34 (2007).
113. Tikkanen J, Heinonen OP: Risk factors for cardiovascular malformations in Finland. Eur. J. Epidemiol. 6, 348-356 (1990).
114. Mazzanti L, Cacciari E: Congenital heart disease in patients with Turner's syndrome. Italian study group for Turner syndrome. Clin. Endocrinol. 54, 69-73 (2001).
115. Korenberg JR, Bradley C, Disteche CM: Down syndrome: molecular mapping of the congenital heart disease and duodenal stenosis. Am. J. Hum. Genet. 50, 294-302 (1992).
116. Perez E, Sullivan KE: Chromosome 22q11.2 deletion syndrome: DiGeorge and velocardiofacial syndromes. Curr. Opin. Pediatr. 14, 678-683 (2002).
117. Yagi H, Furutani Y, Hamada H: Role of TBX1 in human del22q11.2 syndrome. Lancet 362, 1366-1373 (2003).
118. Lowery MC, Morris CA, Ewart A: Strong correlation of elastin deletions, detected by FISH, with Williams syndrome: evaluation of 235 patients. Am. J. Hum. Genet. 57, 49-53 (1995).
119. Tartaglia M, Mehler EL, Goldberg R: Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29, 465-468 (2001).
120. Basson CT, Cowley GS, Solomon SD: The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome). N. Engl. J. Med. 330, 885-891 (1994).
121. McElhinney DB, Krantz JD, Bason L: Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Nat. Genet. 16, 235-242 (1997).
122. Satoda M, Pieropont MEM, Diaz GA: Mutations in TFAP2B cause Charge syndrome, a familial form of patent ductus arteriosus. Nat. Genet. 25, 42-46 (2000).
123. Vissers LE, van Ravenswaaij CM, Admiraal R: Mutations in a new member of the chromodomain gene family cause Charge syndrome. Nat. Genet. 36, 955-957 (2004).
124. Ruiz-Perez VL, Ide SE, Strom TM: Mutations in a new gene for the Ellis-van Creveld syndrome and Weyers acrodental dysostosis. Nat. Genet. 24, 283-286 (2000).
125. Sanlaville D, Genevieve D, Bernardin C et al.: Failure to detect an 8p22-8p23.1 duplication in patients with Kabuki (Niikawa-Kuroki) syndrome. Eur. J. Hum. Genet. 13, 690-693 (2005).
126. Engelen JJ, Moog U, Evers JL: Duplication of chromosome region 8p23.1-p23.3: a benign variant? Am. J. Med. Genet. 91, 18-21 (2000).
127. Nora JJ: Multifactorial inheritance hypothesis for the etiology of congenital heart diseases. The genetic-environmental interaction. Circulation 38, 604-617 (1968).
128. Jing-bin H, Ying-long L, Pei-Wu S, Xiao-dong L, Ming D, Xiang-Ming F: Molecolar mechanisms of congenital heart disease. Cardiovasc. Pathol. DOI:10.1016/j. carpath.2009.06.008 (2009) (Epub ahead of print).
129. Bruneau G: The developmental genetics of congenital heart disease. Nature 451, 943-948 (2008).
130. Bajolle F, Zaffran S, Bonnet D: Genetics and embryological mechanisms of congenital heart diseases. Arch. Cardiovasc. Dis. 102, 59-63 (2009).
131. Pierpont ME, Craig T, Basson D et al.: Genetic basis for congenital heart defects: current knowledge. Circulation 115, 3015-3038 (2007).
132. Bernier F P, Spaegens R: The geneticist's role in adult congenital heart disease. Cardiol. Clin. 24, 557-569 (2006).
133. Benson WD: The genetics of congenital heart disease: a point in the revolution. Cardiol. Clin. 20, 385-394 (2002).
134. Hartman JLT, GarvikB, Hartwell L: Principles for the buffe ring of genetics variation. Science 291, 1001-1004 (2001).
135. Bentham J, Bhattacharya S: Genetic mechanisms controlling cardiovascular development Ann. NY Acad. Sci. 1123, 10-19 (2008).
136. Van Beynemun IM, Kapusta L, den Heijer M: Maternal MTHFR 677C>T is a risk factor for congenital heart defects: effect modification by periconceptional folate supplementation. Eur. Heart J. 27, 981-987 (2006).
137. Garg V, Kathiriya IS, Barnes R et al.: GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424, 443-447 (2003).
138. Lee Y, Shioi T, Kasahara H: The cardiac tissue-restricted homeobox protein Csx/Nkx2.5 physically associates with the zinc finger protein GATA4 and cooperatively activates atrial natriuretic factor gene expression. Mol. Cell. Biol. 18, 3120-3129 (1998).
139. Sepulveda JL, Belaguli N, Nigam V, Chen CY, Nemer M, Schwartz RJ: GATA-4 and Nkx-2.5 coactivate Nkx-2 DNA binding targets: role for regulating early cardiac gene expression. Mol. Cell. Biol. 18, 3405-3415 (1998).
140. Ching YH, Ghosh TK, Cross SJ et al.: Mutation in myosin heavy chain 6 causes atrial septal defect. Nat. Genet. 37 (4), 423-428 (2005).
141. Garg V, Kathiriya IS, Barnes R et al.: GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424, 443-447 (2003).
142. Matsson H, Eason J, Bookwalter CS et al.: α-cardiac actin mutations produce atrial septal defects. Hum. Mol. Genet. 17, 256-265 (2008).
143. Schott JJ, Benson DW, Basson CT et al.: Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science 281, 108-111 (1998).
144. Shiojima I, Komuro I, Inazawa J et al.: Assignment of cardiac homeobox gene CSX to human chromosome 5q34. Genomics 27, 204-206 (1995).
145. Elliott DA, Kirk EP, Yeoh T et al.: Cardiac homeobox gene NKX2-5 mutations and congenital heart disease: associations with atrial septal defect and hypoplastic left heart syndrome. J. Am. Coll. Cardiol. 41, 2072-2076 (2003).
146. McElhinney DB, Geiger E, Blinder J, Benson DW, Goldmuntz E: NKX2.5 mutations in patients with congenital heart disease. J. Am. Coll. Cardiol. 42, 1650-1655 (2003).
147. Posh M, Perrot A, Schmitt K et al.: Mutations in GATA4, NKX2.5, CRELD1 and BMP4 are infrequently found in patients with congenital cardiac septal defects. Am J. Med. Genet. A 146, 251-253 (2008).
148. Geiger E, Benson DW: NKX2.5 mutations in patients with tetralogy of Fallot. Circulation 104, 2565-2568 (2001).
149. Zhang W, Li X, Ma Z et al.: GATA4 and NKX2.5 gene analysis in Chinese Uygur patients with congenital heart defect. Chin. Med. J. 122, 416-419 (2009).
150. Reamon-Buettner SM, Borlac J: Somatic NKX2.5 mutations as a novel mechanism of disease in complex congenital heart disease. J. Med. Genet. 41, 684-690 (2004).
151. Draus JM, Hauck MA, Goetsch M, Austin EH, Tomita-Mitchell A, Mitchell ME: Investigation of somatic NKX2.5 mutations in congenital heart disease. J. Med. Genet. 46, 115-122 (2009).
152. Hosoda T, Komuro I, Shiojima I et al.: Familial atrial septal defect and atrioventricular conduction disturbance associated with a point mutation in the cardiac homeobox gene CSX/NKX2-5 in a Japanese patient. Jpn Circ. J. 63, 425-426 (2009).
153. Kasahara H, Lee B, Schott JJ et al.: Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease. J. Clin. Invest. 106, 299-308 (2000).
154. Zhu W, Shiojima I, Hiroi Y et al.: Functional analyses of three Csx/Nkx-2.5 mutations that cause human congenital heart disease. J. Biol. Chem. 275, 35291-35296 (2000).
155. Monzen K, Zhu W, Kasai H et al.: Dual effects of the homeobox transcription factor Csx/Nkx2-5 on cardiomyocytes. Biochem. Biophys. Res. Commun. 298, 493-500 (2002).
156. Pauli RM, Scheib-Wixted S, Cripe L, Izumo S, Sekhon GS: Ventricular non-compaction and distal chromosome 5q deletion. Am. J. Med. Genet. 85, 419-423 (1999).
157. Garg V, Kathiriya IS, Barnes R et al.: GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424, 443-447 (2003).
158. Rajagopal SK, Ma Q, Obler D et al.: Spectrum of heart disease associated with murine and human GATA4 mutation. J. Mol. Cell. Cardiol. 43, 677-685 (2007).
159. Hirayam-Yamada K, Kamisago M, Akimoto K et al.: Phenotypes with GATA4 or NKX2.5 mutations in familial atrial septal defect. Am. J. Med. Genet. A 135, 47-52 (2005).
160. Sarkozy A, Conti E, Neri C et al.: Spectrum of atrial septal defects associated with mutations of NKX2.5 and GATA4 transcription factors. J. Med. Genet. 42, E16 (2005).
161. Sarkozy A, Esposito G, Conti E et al.: CRELD1 and GATA4 gene analysis in patients with nonsyndromic atrioventricular canal defects. Am J. Med. Genet. 139 (3), 236-238 (2005).
162. Nemer G, Fadlalah F, Usta J et al.: A novel mutation in the GATA4 gene in patients with tetralogy of Fallot. Hum. Mutat. 27, 293-294 (2006).
163. Zhang L, Tumer Z, Jacobsen JR, Andersen PS, Tommerup N, Larsen LA: Screening of 99 Danish patients with congenital heart disease for GATA4 mutations. Genet. Test. 10, 277-280 (2006).
164. Schluterman MK, Krysiak AE, Kathiriya IS et al.: Screening and biochemical analysis of GATA4 sequence variations identified in patients with congenital heart disease. Am. J. Med. Genet. A 143 A, 817-823 (2007).
165. Tomita-Mitchell A, Maslen CL, Morris CD, Garg V, Goldmuntz E: GATA4 sequence variants in patients with congenital heart disease. J. Med. Genet. 44, 779-783 (2007).
166. Zhang W, Li X, Shen A, Jiao W, Guan W, Li Z: GATA4 mutations in 486 Chinese patients with congenital heart disease. Eur. J. Med. Genet. 51, 527-535 (2008).
167. Sarkozy A, Esposito G, Conti E et al.: CRELD1 and GATA4 gene analysis in patients with nonsyndromic atrioventricular canal defects. Am. J. Med. Genet. 139 (3), 236-238 (2005).
168. Reamon-Buettner SM, Cho SH, Borlak J: Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for congenital heart disease (CHD). Med. Genet. 8, 38 (2007).
169. Kodoa K, Nishizawa T, Furutanib M et al.: GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling. Proc. Natl Acad. Sci. USA 106, 33 (2009).
170. Casey B, Devoto M, Jones K, Ballabio A: Mapping a gene for familial situs abnormalities to human chromosome Xq24-q27.1. Nat. Genet. 403-407 (2003).
171. Defects of Laterality and Looping. Ferencz C, Loffredo CA, Correa-Villasenor A, Wilson PD (Eds). Futura Publishing, Armonk, NY, USA (2007).
172. Gebbia M, Ferrero GB, Pilia G et al.: X-linked situs abnormalities result from mutations in ZIC3. Nat. Genet. 17, 305-308 (1997).
173. Megarbane A, Salem N, Stephan E et al.: Xlinked transposition of the great arteries and incomplete penetrance among males with a nonsense mutation in ZIC3. Eur. J. Hum. Genet. 8, 704-708 (2000).
174. Ferrero GB, Gebbia M, Pilia G et al.: A submicroscopic deletion in Xq26 associated with familial situs ambiguus. Am. J. Hum. Genet. 61, 395-401 (1997).
175. Ware SM, Peng J, Zhu L et al.: Identification and functional analysis of ZIC3 mutations in heterotaxy and related congenital heart defects. Am. J. Hum. Genet. 74, 93-105 (2004).
176. Chhin B, Hatayama M, Bozon D et al.: Elucidation of penetrance variability of a zic3 mutation in a family with complex heart defects and functional analysis of zic3 mutations in the first zinc finger domain Hum. Mutat. 28 (6), 563-570 (2007).
177. Kohlhase J, Chitayat D, Kotzot D et al.: SALL4 mutations in Okihiro syndrome (Duane-radial ray syndrome), acro-renal-ocular syndrome, and related disorders. Hum. Mutat. 26, 176-183 (2005).
178. Kohlhase J, Heinrich M, Schubert L et al.: Okihiro syndrome is caused by SALL4 mutations. Hum. Mol. Genet. 11, 2979-2987 (2002).
179. Kohlhase J, Schubert L, LiebersM et al.: Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy. J. Med. Genet. 40, 473-478 (2003).
180. Borozdin W, Wright MJ, Hennekam RCM et al.: Novel mutations in the gene SALL4 provide further evidence for acro-renal-ocular and Okihiro syndromes being allelic entities, and extend the phenotypic spectrum. J. Med. Genet. 41, E102 (2004).
181. Wang B, Li L, Xie X et al.: Genetic variation of SAL-Like 4 (SALL4) in ventricular septal defect. Int. J. Cardiol. DOI:10.1016/j.ijcard. 2009.05.067 (2009) (Epub ahead of print).
182. Sperling S, Grimm CH, Dunkel I et al.: Identification and functional analysis of CITED2 mutations in patients with congenital heart defects. Hum. Mutat. 26 (6), 575-582 (2005).
183. Reamon-Buettner SM, Ciribilli Y, Inga A, Borlak J: A loss-of-function mutation in the binding domain of HAND1 predicts hypoplasia of the human hearts. Hum. Mol. Genet. 17, 1397-1405 (2008).
184. Reamon-Buettner SM, Ciribilli Y, Traverso I, Kuhls B, Inga A, Borlak J: A functional genetic study identiflies HAND1 mutations in septation defects of the human heart. Hum. Mol. Genet. 18, 3567-3578 (2009).
185. Khetyar M, Syrris P, Tinworth L, Abushaban L, Carter N: Novel TFPA2B mutation in nonsindromic patent ductus arteriosus. Genet. Test. 12, 457-459 (2008).
186. Muncke N, Niesler B, Roeth R et al.: Mutational analysis of the PITX2 coding region revealed no common cause for transposition of the great arteries (dTGA). BMC Med. Genet. 6, 20 (2005).
187. Pizzuti A, Sarkozy A, Newton AL et al.: Mutations of ZFPM2/FOG2 gene in sporadic cases of tetralogy of Fallot. Hum. Mutat. 22, 372-377 (2003).
188. Sarkozy A, Conti E, D'Agostino R et al.: ZFPM2/FOG2 and HEY2 genes analysis in nonsyndromic tricuspid atresia. Am. J. Med. Genet. 133, 68-70 (2005).
189. Gong W, Gottlieb S, Collins J et al.: Mutation analysis of Tbx1 in non-deleted patients with features of DGS/VCFS or isolated cardiovascular defects. J. Med. Genet. 38, E45 (2001).
190. Cabuk F, Karabulut HG, Tuncali T, Karademir S, Bozdayi M, Tudie;kudie;n A: TBX1 gene mutation screening in patients with non-syndromic Fallot Tetralogy. Turk. J. Pediatr. 49 (1), 61-68 (2007).
191. Rauch R, Hofbeck M, Zweier C et al.: Comprehensive genotype-phenotype analysis in 230 patients with Tetralogy of Fallot. J. Med. Genet. DOI: jmg.2009.070391 (2009) (Epub ahead of print).
192. Buettner SM, Borlak J: TBX5 mutations in non-Holt-Oram syndrome (HOS) malformed hearts. Hum. Mutat. 24 (1), 104 (2004).
193. Xin N, Qiu GR, Gong LG, Xu XY, Sun KL: The mechanism of TBX5 abnormal expression in simple congenital heart disease. Yi Chuan. 31 (4), 374-380 (2009).
194. Kirk EP, Sunde M, Costa MW et al.: Mutations in cardiac T-Box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy. Am. J. Hum. Genet. 81, 280-291 (2007).
195. Liu C, Shen A, Li X, Jiao W, Zhang X, Li Z: T-box transcription factor TBX20 mutations in Chinese patients with congenital heart disease. Eur. J. Med. Genet. 51, 580-587 (2008).
196. Megarbane O, Dietz R, Stiller B et al.: A gain-of-function TBX20 mutation causes congenital atrial septal defects, patent foramen ovale and cardiac valve defects. J. Med. Genet. DOI: 10.1136/jmg.2009.069997 (2009) (Epub ahead of print).
197. Shiojima I, Komuro I: Cardiac developmental biology: from flies to humans. Jpn. J. Physiol. 55, 245-254 (2005).
198. Mandel EM, Callis TE, Wang D-Z, Conlon FL: Transcriptional Mechanisms of Congenital Heart Disease 2 (1), Elsevier (2005).